BioCentury | Jun 19, 2020

Lyell, Pact combine T cell techs to take on solid tumors

Lyell and Pact think the union of their T cell engineering technologies could overcome the roadblocks hampering cell therapies for solid tumors. While the partners are still pursuing independent pipelines, the joint program could ultimately...
BioCentury | Apr 4, 2020
Management Tracks

CureVac names Stéphenne chairman; plus Desmond-Hellmann to Pfizer’s board, Reagan-Udall, Kyowa Kirin, Assembly, BioCryst and more

CureVac AG said Deputy Chairman Jean Stéphenne will become chairman. He is the former president and chairman of the biologicals unit of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). It's another management change for the biotech as it...
BioCentury | Apr 3, 2020
Distillery Therapeutics

The bacterial adhesion protein fimH as a cancer immunotherapy adjuvant

DISEASE CATEGORY: Cancer INDICATION: Colorectal cancer; melanoma The E. coli adhesion protein fimH could be used as an adjuvant for cancer immunotherapy. In mice modeling melanoma, administering fimH alongside a tumor antigen increased antigen-specific T...
BioCentury | Mar 13, 2020
Tools & Techniques

How to feed the machine: lessons from an AI antibiotics study

The recent AI-based discovery of broad-spectrum antibiotic candidates highlights the potential of new machine learning methods to find compounds humans might otherwise miss, but ups the ante on the quality and diversity of input data...
BioCentury | Feb 8, 2020
Product Development

As coronavirus disrupts MNC operations in China, companies look to digital solutions

The coronavirus outbreak in China has triggered a stark call to action across the international biopharma community to treat, diagnose and prevent the spread of the virus, but it has also revealed some cracks in...
BioCentury | Jan 31, 2020
Distillery Therapeutics

FERMT2 identified as target in renal fibrosis

DISEASE CATEGORY: Renal INDICATION: Renal damage Inhibiting the focal adhesion molecule FERMT2 could treat renal fibrosis. In renal tissue from patients with renal fibrosis, FERMT2 levels were higher in fibrotic tissue than in normal tissue....
BC Innovations | Dec 20, 2019
Product Development

Rise of the first-time biotech CEO

A shortage of management talent is creating opportunities for more first-time CEOs to experience the top job. While this could open the door to more diverse executive teams, there’s no sign of that happening organically....
BioCentury | Aug 17, 2019
Emerging Company Profile

Impact casting a wide synthetic lethality net

After laying the foundation with its PARP inhibitor, Impact plans to build a comprehensive synthetic lethality pipeline across known DNA damage repair targets and new ones outside of DDR to address a wider range of...
BC Innovations | Aug 8, 2019
Distillery Therapeutics

Endocytosis protein decoy for reducing TRPV1-associated pain

DISEASE CATEGORY: Neurology INDICATION: Pain Blocking phosphorylation of endocytosis protein AP2M2 to induce internalization of TRPV1, a membrane channel associated with analgesia and hyperalgesia, could treat spontaneous pain and inflammatory thermal hyperalgesia. In an in...
BC Innovations | Aug 8, 2019
Distillery Therapeutics

CDK7 inhibition for drug-resistant cancers

DISEASE CATEGORY: Cancer INDICATION: Brain cancer; sarcoma; solid tumors Inhibiting CDK7 could treat hedgehog signaling-driven cancers resistant to SMO inhibitors. A CDK7 inhibitor tool compound decreased viability of cells resistant to SMO inhibitors and driven...
Items per page:
1 - 10 of 338